AGER Polyclonal antibody

Verified Samples in WB: Mouse lung, Rat lung
Verified Samples in IHC: Human lung

WB 1:5000-1:10000, IHC 1:100-1:200

Polyclonal

IgG

Recombinant Human AGER protein expressed by Mammalian

AGER

MGC, SCARJ, AGER, RAGE, SCARJ1, Advanced glycosylation end product-specific receptor, advanced glycosylation end-product specific receptor, MGC2235, Receptor for Advanced Glycation End products, Receptor for advanced glycosylation end products

42 kDa

43 kDa

Secreted, Cell membrane

Endothelial cells.

1 mg/mL

Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

PBS with 0.05% proclin 300, 1% protective protein and 50% glycerol,pH7.4

Antigen Affinity Purification

Neuroscience, Cardiovascular

Unconjugated

AGER (Advanced Glycosylation End-Product Specific Receptor) is a Protein Coding gene. Diseases associated with AGER include Diabetic Angiopathy and Hyperglycemia. Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans. Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. These ligands accumulate at inflammatory sites during the pathogenesis of various diseases, including diabetes, vascular complications, neurodegenerative disorders, and cancers and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction or inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B.